Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial.

Karen L Madsen Astrid Emilie Buch Bruce H Cohen Marni J FalkAngela GoldsberryAmy GoldsteinAmel KaraaMary Kay KoenigColleen C MurareskuColin MeyerMegan O'GradyFernando ScagliaPerry B ShiehJerry Vockley Zarazuela Zolkipli-CunninghamRonald G HallerJohn Vissing

Published in: Neurology (2020)

This study provides Class II evidence that, for patients with mitochondrial myopathy, omaveloxolone compared to placebo did not significantly change peak exercise workload.

Keyphrases

oxidative stress
late onset
phase iii
clinical trial
study protocol
high intensity
physical activity
muscular dystrophy
phase ii
randomized controlled trial
resistance training
open label